Dechra Pharmaceuticals PLC Director/PDMR Shareholding (5922Q)
01 December 2016 - 2:04AM
UK Regulatory
TIDMDPH
RNS Number : 5922Q
Dechra Pharmaceuticals PLC
30 November 2016
30 November 2016
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Sale of shares:
Dechra Pharmaceuticals PLC announces that on 30 November 2016,
Ian Page and Tony Griffin sold the shares set out below (acquired
pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan
exercise announced on 29 November 2016) in order to fund the
resulting tax liability.
Name Capacity Shares Sale Total beneficial Percentage
Sold Price shareholding of issued
per share following share capital
this announcement
Ian Page Director/PDMR 58,633 GBP12.80 817,908 0.879%
Tony Griffin Director/PDMR 17,133 GBP12.92 52,104 0.056%
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the EU Market Abuse
Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial
Responsibility ("PDMR")/person closely
associated with them ("PCA")
--- -----------------------------------------------------------------
a) Name Ian Page
--- ----------------------------- ----------------------------------
2. Reason for the notification
--- -----------------------------------------------------------------
a) Position/status Director/PDMR
--- ----------------------------- ----------------------------------
b) Initial notification/ Initial Notification
amendment
--- ----------------------------- ----------------------------------
3. Details of the Issuer
--- -----------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--- ----------------------------- ----------------------------------
b) LEI code N/A
--- ----------------------------- ----------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------------
a) Description Ordinary Shares of 1 pence
of the financial each
instrument
Identification ISIN: GB0009633180
code
--- ----------------------------- ----------------------------------
b) Nature of Partial sale of shares obtained
the transaction under the Company's Long Term
Incentive Plan to satisfy
tax liability
--- ----------------------------- ----------------------------------
c) Price(s) and Price(s) Volume(s)
volumes(s)
GBP12.80 58,633
--- ----------------------------- ---------------- ----------------
d) Aggregated
information
* Aggregate volume N/A
* Price
--- ----------------------------- ----------------------------------
e) Date of the 2016.11.30
transaction
--- ----------------------------- ----------------------------------
f) Place of the London Stock Exchange
transaction
--- ----------------------------- ----------------------------------
1. Details of the Person Discharging Managerial
Responsibility ("PDMR")/person closely
associated with them ("PCA")
--- -----------------------------------------------------------------
a) Name Tony Griffin
--- ----------------------------- ----------------------------------
2. Reason for the notification
--- -----------------------------------------------------------------
a) Position/status Director/PDMR
--- ----------------------------- ----------------------------------
b) Initial notification/ Initial Notification
amendment
--- ----------------------------- ----------------------------------
3. Details of the Issuer
--- -----------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--- ----------------------------- ----------------------------------
b) LEI code N/A
--- ----------------------------- ----------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------------
a) Description Ordinary Shares of 1 pence
of the financial each
instrument
Identification ISIN: GB009633180
code
--- ----------------------------- ----------------------------------
b) Nature of Partial sale of shares obtained
the transaction under the Company's Long Term
Incentive Plan to satisfy
tax liability
--- ----------------------------- ----------------------------------
c) Price(s) and Price(s) Volume(s)
volumes(s)
GBP12.92 17,133
--- ----------------------------- ---------------- ----------------
d) Aggregated
information
* Aggregate volume N/A
* Price
--- ----------------------------- ----------------------------------
e) Date of the 2016.11.30
transaction
--- ----------------------------- ----------------------------------
f) Place of the London Stock Exchange
transaction
--- ----------------------------- ----------------------------------
For further information, please contact:
Suzana Cross, General Counsel and Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHAKKDKPBDDNDN
(END) Dow Jones Newswires
November 30, 2016 10:04 ET (15:04 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024